Viavi Solutions Inc. (VIAV) is not a strong buy at the moment for a beginner investor with a long-term focus. Despite positive growth in revenue and strong analyst ratings, the stock's recent significant price drop, negative financial performance in terms of net income and EPS, and lack of strong proprietary trading signals suggest waiting for stabilization before investing.
The stock is showing mixed signals. The MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 36.962, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its key support level (S1: 27.602), with significant downside risk if it breaks below this level.

Analysts have consistently raised price targets, with strong buy ratings and optimism about growth in the Data Center ecosystem and Aerospace & Defense sales.
Revenue increased by 36.37% YoY in fiscal Q2 2026, driven by high-speed Ethernet demand and AI advancements.
The company is well-positioned in the AI and optical infrastructure markets, which are expected to grow.
The stock experienced a sharp decline of -10.06% in the regular market and an additional -0.93% in post-market trading, raising concerns about near-term stability.
Financial performance in fiscal Q2 2026 showed a significant drop in net income (-628.57% YoY) and EPS (-625.00% YoY), indicating profitability challenges.
Insider selling by the CMO on March 3, 2026, may signal a lack of confidence in the stock's short-term performance.
In fiscal Q2 2026, revenue grew by 36.37% YoY to $369.3M, but net income dropped significantly to -$48.1M (-628.57% YoY), and EPS fell to -0.21 (-625.00% YoY). Gross margin also declined to 55.32%, down 6.25% YoY, reflecting cost pressures or inefficiencies.
Analysts are highly optimistic about Viavi, with multiple firms raising price targets and maintaining Buy or Positive ratings. The most recent price target from Needham is $36, reflecting confidence in growth from acquisitions and the Data Center ecosystem. However, the stock's current price of $27.76 is well below these targets.